Less than two months after Genomica Corp. announced a change in strategic direction, resulting from disappointing market penetration of its third-party enterprise bioinformatics software, the company has agreed to be acquired by Exelixis Inc. for $110 million in stock. Not coincidentally, Genomica is sitting with precisely the same amount of cash, making the deal in essence a back-door follow-on offering for Exelixis, which gets Genomica's software and technology base for a song. And that fact speaks volumes about the sustainability of a software-based bioinformatics business.
In October, Genomica restructured, cutting its workforce by two-thirds to preserve both its position in the market and its cash...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?